Oncology

 

Oncology

Measuring Biomarkers
at Every Stage
of Tumor Development

The ability to detect oncology biomarkers at ultra-low levels is enabling new options for diagnostics and treatment in cancer research.

Simoa assays can be used to monitor cancer risk, identify early stage cancers and discriminate between benign and malignant cells. Simoa biomarkers can be used prognostically to predict disease outcome, predict progression free survival and monitor reoccurrence. Assays can also be used to monitor sensitivity to therapy and to aid in treatment decisions.

Latest News

05.10
Ligand-binding techniques such as immunoassays, the reference for clinical diagnosis, offer a wide range of innovative approaches based on signal DNA amplification, nanotechnologies or digital assays, which result in technologies with sensitivities more than 1000-times that of formats used 20 years…
03.15
We were honored to be able to speak about the promise of immuno-oncology (IO) therapeutics at this year’s Molecular Med Tri-Con conference and the 12th Annual Biomarkers Congress.